- Home
- LEN vs ASND Comparison
LEN vs ASND Comparison
Compare LEN & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEN | ASND |
|---|---|---|
| Founded | 1954 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8B | 17.7B |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LEN | ASND |
|---|---|---|
| Price | $82.24 | $227.74 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $97.23 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 4.1M | 773.2K |
| Earning Date | 06-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $34,186,934,000.00 | N/A |
| Revenue This Year | N/A | $96.35 |
| Revenue Next Year | $4.41 | $44.91 |
| P/E Ratio | $37.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $75.70 | $186.05 |
| 52 Week High | $133.76 | $282.15 |
Technical Indicators
Market Signals| Indicator | LEN | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 37.16 |
| Support Level | $81.50 | $213.28 |
| Resistance Level | $89.39 | $246.56 |
| Average True Range (ATR) | 2.33 | 9.61 |
| MACD | 0.44 | -2.67 |
| Stochastic Oscillator | 77.68 | 14.38 |
Price Performance
Historical ComparisonAbout LEN Lennar Corporation
Lennar is the second-largest public homebuilder in the United States, behind D.R. Horton, operating in 26 states. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.